{"id":512,"title":"NAD+ precursor fails in Parkinson’s disease","title_zh":"NAD+前体在帕金森病治疗中未获成功","url":"https://doi.org/10.1038/s43587-026-01277-x","doi":"10.1038/s43587-026-01277-x","pmid":null,"journal":"Nature Aging","kind":"paper","lang":"en","published_at":"2026-11-06T00:00:00+00:00","fetched_at":"2026-11-08T03:45:21+00:00","authors":["Michael Attwaters"],"primary_topic":"repro-aging","topics":[{"slug":"repro-aging","score":3.0,"hits":["nad+"]}],"topic_score":3.0,"preference_score":0.0,"preference_labels":[],"llm_score":38.0,"final_score":46.0,"score_dims":{"novelty":45,"rigor":25,"impact":20,"relevance":8,"translation":10},"recommend_reason":"内容为神经退行性疾病（帕金森病）领域的 NAD+ 前体阴性结果评述，与生殖医学、辅助生殖及胚胎研究无直接关联；且无摘要、无法评估设计与数据，对生殖衰老方向仅有间接的概念性提示，不建议作为本领域必读。","keywords":["NAD+前体","帕金森病","临床试验阴性结果","衰老干预","烟酰胺腺嘌呤二核苷酸"],"selected":0,"story_id":null,"llm_provider":"deepseek","llm_model":"deepseek-flash","llm_effort":"low","source_key":"crossref-cns","source_name":"Crossref · CNS 与大子刊新上线（领域过滤）","source_tier":1,"mention_count":1,"has_interpretation":false,"journal_key":"nat-aging","journal_tier":"cns-sub","journal_if":17.0,"is_mock":false,"summary_zh":"该文为 Nature Aging 刊出的短篇评述（作者 Michael Attwaters），报道 NAD+ 前体补充在帕金森病中的干预未能取得预期疗效。原文未提供摘要，因此具体试验对象、给药方案、样本量、主要终点与统计结果均无法从现有材料确认；可判断的核心信息是：靶向 NAD+ 代谢的干预在帕金森病人群中未显示获益，对“补充 NAD+ 前体可延缓年龄相关神经退行”的假设构成负面证据。该结论提示同类抗衰老干预的临床转化需更谨慎的终点设计与人群选择。","summary":"","interpretation_basis":null,"fulltext_status":null,"interpretation":null,"fulltext":{"available":false,"status":null,"reason":"尚未抓取全文（未入选、分数未达阈值，或还没跑 fulltext 步骤）","pmcid":null,"license":null,"chars":0,"source":null,"fetched_at":null}}